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ABSTRACT A critical appraisal and clinical application of Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, 
Aracil C. Transfusion strategies for acute upper gastrointestinal bleeding. New Eng J Med. 2013;368(1):11-21. doi: 
10.1056/NEJMoa1211801. 
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Clinical Context 
The patient is a 70 year old man with a past medical history of hypertension, hyperlipidemia, peripheral vascular 
disease, abdominal aortic aneurysm repair, and coronary artery disease. He presented to the Emergency 
Department complaining of a two-day history of dark stool associated with dizziness, tremulousness, bilateral 
facial dysesthesia, and generalized weakness. He stated, “My sleep has been bad and I’ve been fatigued and weak 
before this, but now it seems worse.” Upon presentation, the patient’s vital signs were stable. Fecal occult blood 
testing was positive, patient was transferred to the general medicine floor, Plavix and aspirin were held, and 
gastroenterology was consulted.  
After admission, the patient was boarded to undergo an endogastroduodenoscopy but that night his hemoglobin 
fell from 9.1 g/dL to 7.1 g/dL. At admission, he understood that blood transfusion might be necessary during his 
hospital stay. He stated, “I understand; I’ll take a transfusion if it will help me.” He was transfused with two units 
packed red blood cells and one unit of platelets. Subsequent to transfusion his hemoglobin level rebounded to 9.5 
g/dL. Following transfusion, his symptoms, while still present, had improved. 
He lives at home with his wife and anxiety over his recent health concerns was affecting his personal life and day to 
day activities. He was feeling overwhelmed and nervous about his admission. He had a 70 pack-year smoking 
history, but stated he quit “a year ago”. He used to drink about a pint of liquor every day but he quit four weeks 
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ago. He saw his primary care physician 10 days prior to admission complaining of difficulty falling asleep and 
staying asleep and depressed mood. His PCP prescribed melatonin to help him sleep and sertraline for depression, 
but patient said he hadn’t experienced any relief with either. 
The patient had the abdominal aortic aneurysm repair two months prior and had been following with the vascular 
surgeon. On rounds, our team told him that he was losing blood and that we would try to find the site of blood loss 
during this hospitalization. At this point, the patient said, “I hope my artery repair isn’t leaking.” The team 
reassured him that it was unlikely that his prior surgery was causing any of his current signs or symptoms. We 
informed him that the dark color of his stools led us to believe that his bleeding in his GI tract. 
Our attending asked, “Did you counsel him about the risks of harm and risks of benefit from transfusion with a 
hemoglobin of 7.1?” 
Clinical Question 
For patients with a recent upper gastrointestinal (GI) bleed, is it appropriate to transfuse a patient who has a hemoglobin of 7.1 
g/dl ? 
Research Article 
Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C. Transfusion strategies for acute upper gastrointestinal 
bleeding. New Eng J Med. 2013;368(1):11-21. doi: 10.1056/NEJMoa1211801 
Related Literature 
The search started in Google Scholar using the following search term: “For gastrointestinal bleeding when is transfusion 
appropriate?” The first two citations revealed an article thought to be relevant to our patient1 and a guideline.2 These two citations 
were reviewed on PubMed. The "similar articles" recommendations were reviewed for new studies, as well as the "cited by 
systematic reviews" list. A Cochrane review was found3, and the systematic review results were read. A PubMed search was also 
done with search terms (transfus*[tiab] AND "threshold") AND (gastrointestinal OR "gi bleed"). After this process, ultimately three 
total randomized, controlled trials were identified that studied outcomes of transfusion in patients with acute GI bleeding.1,4,5 The 
TRIGGER trial was a pragmatic open-label, cluster randomized feasibility trial that sought to confirm the Villanueva trial, published 
two years earlier.5 The outcomes measured were specific to feasibility and not designed to be direct evidence related to the 
question. The Blair trial was a pilot study, which investigated different transfusion thresholds.4 Mortality was investigated as a 
secondary outcome and showed a trend towards reduced mortality in patients with less transfusion. Due to the exploratory nature 
of the study, only 50 subjects were studied. The strongest design with the largest sample size was the Villanueva trial, so it was 
chosen for review.1 
Critical Appraisal 
All three randomized trials are consistent in demonstrating equivalence or benefit with restrictive transfusion strategies and because 
this has also been shown in other clinical settings the strength of recommendation taxonomy for this body of literature is A. For the 
paper reviewed the strength of recommendation taxonomy is level 1.6  
This study was a nonblinded randomized controlled trial at a single institution comparing restrictive versus liberal transfusion 
protocols in the setting of acute upper GI bleed. Restrictive transfusion was defined as a transfusion at hemoglobin of 7 g/dl or less 
with target goal of 7-9 post transfusion versus liberal transfusion which is defined as transfusion at hemoglobin of 9 g/dl with a 
target goal of 9-11. There was no commercial sponsorship for the study. 
Patients greater than eighteen years old who had melena, hematemesis, or both were eligible to participate. There were multiple 
exclusion criteria including but not limited to: patient declining blood transfusion, acute bleeding emergencies, unstable cardiac 
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conditions, or recent surgery. Patients with lower GI bleeding were not eligible. Patients who were completely stable based on 
ROCKALL score also were not included.7 Based on these inclusion and exclusion criteria, the patient described in the clinical scenario 
is similar to the patients in the study. 
Randomization occurred immediately after admission using computer-generated random numbers with block size of 4, stratified for 
presence or absence of cirrhosis. The research paper did not describe how eligible patients were identified, creating a potential 
selection bias. 
Doctors could exclude individual patients based on clinical judgment alone, creating a potential source of selection bias by 
decreasing the number of participants who are potentially medically unstable. 
Because this is an open label trial, the largest potential bias could be greater efforts to monitor and treat patients in what might’ve 
been considered a higher risk category. Although the authors described re-bleeding (45 patients in restrictive group and 71 patients 
in liberal transfusion group), they do not specify whether they maintain the same cut off for transfusion on the second bleed 
compared to the first bleed.  
All-cause mortality within the first 45 days was the primary outcome measure. Twenty-three people in the restrictive transfusion 
strategy (N=444) died. Forty-one people in the liberal transfusion strategy (N=445) died. Number needed to treat was 25 for 
restrictive protocol compared to liberal protocol over the first forty-five days to prevent one death. The hazard ratio for death 
favored restrictive therapy, 0.55 [95% CI 0.33-0.92, p=0.02. Only 3.5% of patients withdrew from the study and the analysis was 
done with an intention to treat protocol. 
Clinical Application 
With regards to our patient, his primary concern rested with the source and control of his bleeding. This was 
especially evident with his concern for abdominal aneurysmal rupture for which he knew the prognosis would be 
poor. At esophagogatroduodonoscopy, he was found to have mild gastritis and minimal peptic disease. The patient 
was pleased with the relatively benign diagnosis, but we encouraged him to continue to deal with his other life 
stresses. 
Applying the chosen study to our patient, we wondered if he would have done just as well without the 
transfusions. Our clinical scenario mirrors many aspects of the study appraised. However, the study was not 
designed to stratify the rate of blood loss, as the argument could be made that a more rapidly decreasing 
hemoglobin may warrant a blood transfusion even when hemoglobin levels return above the suggested restrictive 
threshold. Thus, the benefit of applying a restrictive hemoglobin level threshold for transfusion of 7.0 mg/dL may 
indeed be evident for patients with mild to moderate upper gastrointestinal bleeding, whereas using this approach 
in patient with more severe bleeding (perhaps evidenced by more rapidly decreasing serum hemoglobin levels) 
may result in a delay of life saving treatment. 
Alternatively, the harm of transfusing blood products to patients with higher more “liberal” hemoglobin levels is 
multifactorial, including subjecting the patient to potential transfusion reactions, blood product infections, and 
unnecessary healthcare spending. Our patient did in fact meet inclusion criteria for this study and we believed that 
he was a good candidate for a restrictive transfusion threshold.  
Lessons learned: 
1. Through this experience our team has come to the agreement that there is indeed a large disparity in 
knowledge with respect to the risk versus benefits of a liberal versus a restrictive blood transfusion strategy. 
2. Patients continue to be transfused “liberally” despite evidence that this may be in fact be harmful to the 
patient and less effective than the alternative more restrictive approach. This was reinforced when two 
different Intensive Care Unit intensivists used differing thresholds for similar patients on two sequential days. 
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3. As with most aspects of medicine, our understanding of appropriate treatment strategies for different disease 
states continues to expand; it is our professional duty and obligation to propagate this information amongst us 
for the benefit of the patient. 
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